Dope Launches New Cash Cow Business with Skin Booster and Regenerative Injections

Dope ​is expanding its business portfolio with⁣ the launch of a ‌new cosmetic​ medical device business, including skin booster and regenerative injections. This strategic move aims to maximize synergy with its ‌main business, human tissue transplant​ materials.

Skin​ Booster and Regenerative Injections to be Commercialized⁢ Starting Next Month

According to industry sources, Dope’s skin booster and regenerative injections will be ⁢commercialized starting next month and will contribute to the company’s sales in the fourth quarter. This new business is ⁤expected to generate at least 3 ⁣billion won in additional sales by the end of the year.

Expected Sales Growth of Over ‌200% This⁤ Year

Thanks to this new ⁢business, Dope is expected to see‌ sales growth of over 200% this year compared⁢ to the previous year. The⁣ company had sales of about ​6.3 billion won⁤ last year, and conservative estimates suggest that⁣ it will achieve sales of about 18 billion won this⁢ year.

Cosmetic Medical Device Business to Generate Over 15 Billion Won⁢ in Sales Next Year

Dope expects to generate sales of ​over 15⁢ billion won in the cosmetic medical device business alone next year. This will lead to external‌ growth next year that is no less than this year.

Joint‌ Sales Agreement with Dongbang Medical

Dongbang Medical, a ‍hyaluronic acid filler manufacturer and exporter, has partnered with Dope to jointly sell fillers containing extracellular matrix such as collagen‌ and cosmetic skin boosters overseas.

Skin Booster ‘SC Fill Putty’ to be Released in ​Taiwan in⁤ October

The product expected to see the greatest performance growth in the future is the Skin Booster ‘SC Fill Putty’. It is a filler that promotes collagen production in the⁤ face and is scheduled to be released for the first time in‌ Taiwan in October. This product is characterized by securing effects ⁢and safety similar to ‘Sculptra’ by Galderma, the world’s largest skin booster company.

CEO Shin Emphasizes Convenience and Safety of SC Fill Putty

Shin Yong-woo, CEO of Dope, emphasized, “SC Fill Putty is a ‌pre-filled syringe formulation, which increases convenience for both patients‍ and doctors.” He also said, “It does not have ‍the side effects of the most commonly used⁢ hyaluronic acid (HA) filler, such as swelling, bruising, pain, allergic reactions, and inflammation.”

Joint ⁣Product with Pharma Research to be Released in Q3

A joint ‌product with regenerative medicine specialist Pharma Research is also planned to be introduced within the third quarter. A representative example is ‘Cesium L’, ‍an injectable for⁤ the purpose of ‌reconstructing and ⁢treating soft ​tissues using Dope’s supercritical carbon dioxide ⁤decellularization technology.

Supercritical Carbon Dioxide Decellularization Technology

Supercritical carbon dioxide decellularization is an eco-friendly technology that⁣ excludes chemicals such as ‌surfactants that were widely used in the decellularization ‌process and uses carbon dioxide. Decellularization is a process that must be completed in order⁣ to‌ transplant human tissue. Dope ‌was the first in the world ⁤to apply supercritical carbon dioxide decellularization technology and successfully commercialized human tissue transplant materials.

CEO Shin on the ⁢Future of the Company

CEO Shin said, “In addition to these products, Dongbang Medical and Skin Booster ‘EXOCLEO’ are also planning to enter the global market, including South America, in the third and fourth quarters,” and “We will lead the industry’s‌ innovation⁣ while achieving stable growth through diversification ⁣of‌ our revenue structure.”